ClinicalTrials.gg
CompletedNCT00712881Updated Feb 23, 2024Results posted

Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer

A Phase 2 interventional study of Liposomal doxorubicin hydrochloride and Cyclophosphamide in Breast Cancer, sponsored by Cephalon, Inc.. Completed at 22 sites in 6 countries. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-02-23.

Sponsored by Cephalon, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing liposomal doxorubicin in Breast Neoplasms — 5 open to participants now, 9 under way, 2 of them phase 3. liposomal doxorubicin · Breast Neoplasms.

Enrollment
18th of 66
126 · median 57
Started
2008
with 4 others
Phase 2
37 of 67
2 open now
Registered
31st of 67
by date

Among the 67 studies testing liposomal doxorubicin in Breast Neoplasms, this one is the 18th largest by enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2008, is one of 37 in phase 2, and was the 31st registered.

Breast Neoplasms

14,832 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 67 studies testing liposomal doxorubicin in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About liposomal doxorubicin

liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing liposomal doxorubicin in Breast Neoplasms, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of treatment with MYOCET® (doxorubicin hydrochloride) in combination with cyclophosphamide and trastuzumab, 4 cycles, followed by docetaxel plus trastuzumab, 4 cycles, in women with stage II or III breast cancer whose tumour overexpresses the human epidermal growth factor receptor 2 (HER2) gene.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Treatment-naive participants with stage II or III invasive breast cancer (proven histologically/cytologically) and with tests showing an overexpressing of .
  • Participants have at least 1 bidimensionally according to the World Health Organization (WHO) criteria.
  • The participant has an (ECOG) performance status of 0 or 1.
  • The participant has an of at least 55% as assessed by multigated acquisition (MUGA) scan (preferred) or echocardiography.
  • The participant has hematology and serum chemistry laboratory test results within specific protocol-defined ranges.
  • Women of must use a medically accepted method of and must agree to continue use of this method for the duration of the treatment period and for 6 months after the last administration of study drug.

Main Exclusion Criteria:

The participant:

  • Has received previous cancer therapy for breast cancer.
  • Has any history of CHF, angina pectoris, or myocardial infarction.
  • Has uncontrolled hypertension.
  • Has infection, peptic ulcer, or unstable diabetes mellitus.
  • Has been treated with within 8 weeks before the first administration of study drug.
  • Has impaired hepatic or renal function.
  • Is a pregnant or lactating woman. (Any women becoming pregnant during the study will be withdrawn from the study.)
  • Has used an drug within one month before the screening visit.
  • Has a known to any of the study drugs or to their active ingredients.
  • Has an inflammatory breast cancer.
  • Has had any other within five years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer).

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH)

    Participants will receive MCH (liposomal doxorubicin hydrochloride \[60 milligrams {mg}/square meter {m\^2}\], cyclophosphamide (600 mg/m\^2), and trastuzumab (8 or 6 mg/kilogram {kg}), administered as intravenous (IV) infusion on Day 1 of each of 4 consecutive 21-day cycles. For the first cycle, the loading dose of trastuzumab will be 8 mg/kg; 6 mg/kg will be used for the remaining cycles. After 4 cycles of MCH, the treatment will be changed to 4 consecutive 21-day cycles of TH (docetaxel \[100 mg/m\^2\] and trastuzumab \[6 mg/kg\]).

    Drug: Liposomal doxorubicin hydrochloride · Drug: Cyclophosphamide · Drug: Trastuzumab · Drug: Docetaxel

  • Active comparator
    Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH)

    Participants will receive AC (free doxorubicin hydrochloride \[60 mg/m\^2\] and cyclophosphamide \[600 mg/m\^2\]), administered as IV infusion on Day 1 of each of 4 consecutive 21-day cycles. After 4 cycles of AC, the treatment will be changed to 4 consecutive 21-day cycles of TH (docetaxel \[100 mg/m\^2\] and trastuzumab \[8 or 6 mg/kg\]). For the first cycle, the loading dose of trastuzumab will be 8 mg/kg; 6 mg/kg will be used for the remaining cycles.

    Drug: Cyclophosphamide · Drug: Trastuzumab · Drug: Free doxorubicin hydrochloride · Drug: Docetaxel

Interventions

  • Liposomal doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.

    Also known as: Myocet®

  • Cyclophosphamide will be administered per dose and schedule specified in the arm description.

  • Trastuzumab will be administered per dose and schedule specified in the arm description.

  • Free doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.

    Also known as: Anthracycline

  • Docetaxel will be administered per dose and schedule specified in the arm description.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Exhibiting a Pathological Complete Response (pCR) in Breast

    The pCR of breast was based upon histologic examination, as confirmed by a central panel of experts, of resected tissue .

    Time frame: At the end of Cycle 8 (each cycle length = 21 days)

Secondary outcomes

  1. Percentage of Participants Who Achieved an Objective Response (Complete Response [CR] or Partial Response [PR]), as Defined by World Health Organization (WHO) Guidelines

    CR: Disappearance of the lesions and no new lesions. In case of bone metastasis a CR is represented by the normalization of radiography or the complete sclerotic healing of lytic area. PR: In the case of bidimensionally measurable lesions/tumors, a decrease by at least 50% of the sum of the products of the largest perpendicular diameters of each individual lesion/tumor. In the case of unidimensionally measurable lesions a decrease by at least 50% in the largest linear tumour measurement. In the case of non-measurable but evaluable lesions an appreciable change of lesions referable to disease improvement. For bone lesions partial decrease in size or recalcification of lytic areas. No lesion should have progressed and no new lesion should appear.

    Time frame: At the end of Cycle 8 (each cycle length = 21 days)

  2. Percentage of Participants With Class III or IV New York Health Association (NYHA) Congestive Heart Failure (CHF)

    Occurrence of Class III or IV (NYHA) CHF has been reported. Class III: Participants with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain. Class IV: Participants with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.

    Time frame: Baseline up to the end of Cycle 8 (each cycle length = 21 days)

  3. Change From Baseline in Left Ventricular Ejection Fraction (LVEF)

    The LVEF is a fraction of blood (in percent) pumped out of the left ventricle of the heart (the main pumping chamber). LVEF was measured using multigated acquisition (MUGA) or echocardiography.

    Time frame: Baseline, up to 5 years

  4. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. The TEAE was an AE that began or worsened after treatment with study drug. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.

    Time frame: Baseline up to the end of Cycle 8 (cycle length = 21 days)

  5. Percentage of Participants With Progression or Death

    Progression was defined as a 25% or more increase in the size of the lesion or appearance of new lesion. If the participant did not develop an event (disease progression or death), the participant was censored at the last known tumor assessment date (or last follow-up visit without progression documented).

    Time frame: Up to 5 Years after randomization

  6. Percentage of Participants Achieving a Pathological Complete Response (pCR) in Breast and Node

    The pCR of breast and node was based upon histologic examination, as confirmed by a central panel of experts, of breast tissue resected.

    Time frame: At the end of Cycle 8 (each cycle length = 21 days)

  7. Number of Participants Undergoing Breast Conservative Surgery

    Time frame: At the end of Cycle 8 (each cycle length = 21 days)

  8. Severity of Adverse Events as Characterized by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)

    AEs were recorded and graded per the NCI CTCAE scale. The NCI CTCAE is a toxicity scale used to grade the severity of adverse events experienced with cancer treatment. Grade 1= Mild; Grade 2= Moderate; Grade 3= Severe; Grade 4= Life-threatening or disabling; Grade 5= Death related to AE. For summaries for the toxicity grade, participants were counted once at the greatest NCI CTCAE grade.

    Time frame: Up to Week 24

07

Results

Posted Feb 23, 2024

Participant flow

Participant flow — Overall Study
MilestoneDoxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH)Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH)
Started6363
Received at least 1 dose of study drug6263
Completed 8 cycles of treatment5556
Completed5356
Not completed107
Withdrew: Adverse event33
Withdrew: Withdrawal by subject11
Withdrew: Disease progression21
Withdrew: Lost to follow-up11
Withdrew: Non-compliance to study procedures10
Withdrew: Protocol violation11
Withdrew: Randomized but not treated10

Outcome measures

PrimaryPercentage of Participants Exhibiting a Pathological Complete Response (pCR) in Breast

The pCR of breast was based upon histologic examination, as confirmed by a central panel of experts, of resected tissue .

Time frame:
At the end of Cycle 8 (each cycle length = 21 days)
Reported as:
Number · percentage of participants
Percentage of Participants Exhibiting a Pathological Complete Response (pCR) in Breast
percentage of participantsDoxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH)Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH)
Percentage of Participants Exhibiting a Pathological Complete Response (pCR) in Breast41.354.0
Statistical analysis
  • Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH) vs Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH) · 2-sided, binomial proportions · p = 0.154 (Threshold for significance at 0.05 level.)
SecondaryPercentage of Participants Who Achieved an Objective Response (Complete Response [CR] or Partial Response [PR]), as Defined by World Health Organization (WHO) Guidelines

CR: Disappearance of the lesions and no new lesions. In case of bone metastasis a CR is represented by the normalization of radiography or the complete sclerotic healing of lytic area. PR: In the case of bidimensionally measurable lesions/tumors, a decrease by at least 50% of the sum of the products of the largest perpendicular diameters of each individual lesion/tumor. In the case of unidimensionally measurable lesions a decrease by at least 50% in the largest linear tumour measurement. In the case of non-measurable but evaluable lesions an appreciable change of lesions referable to disease improvement. For bone lesions partial decrease in size or recalcification of lytic areas. No lesion should have progressed and no new lesion should appear.

Time frame:
At the end of Cycle 8 (each cycle length = 21 days)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an Objective Response (Complete Response [CR] or Partial Response [PR]), as Defined by World Health Organization (WHO) Guidelines
percentage of participantsDoxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH)Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH)
Percentage of Participants Who Achieved an Objective Response (Complete Response [CR] or Partial Response [PR]), as Defined by World Health Organization (WHO) Guidelines77.884.1
SecondaryPercentage of Participants With Class III or IV New York Health Association (NYHA) Congestive Heart Failure (CHF)

Occurrence of Class III or IV (NYHA) CHF has been reported. Class III: Participants with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain. Class IV: Participants with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.

Time frame:
Baseline up to the end of Cycle 8 (each cycle length = 21 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Class III or IV New York Health Association (NYHA) Congestive Heart Failure (CHF)
percentage of participantsDoxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH)Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH)
Percentage of Participants With Class III or IV New York Health Association (NYHA) Congestive Heart Failure (CHF)00
SecondaryChange From Baseline in Left Ventricular Ejection Fraction (LVEF)

The LVEF is a fraction of blood (in percent) pumped out of the left ventricle of the heart (the main pumping chamber). LVEF was measured using multigated acquisition (MUGA) or echocardiography.

Time frame:
Baseline, up to 5 years
Reported as:
Mean · percentage of blood pumped out
Change From Baseline in Left Ventricular Ejection Fraction (LVEF)
percentage of blood pumped outDoxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH)Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH)
Change at Cycle 4-1.5 ± 6.5-1.0 ± 5.3
Change at Pre-surgery Visit-0.8 ± 7.1-3.4 ± 6.4
Change at Post-surgery Visit-1.6 ± 7.3-3.6 ± 5.7
Change at Month 12-0.9 ± 7.0-4.4 ± 8.0
Change at Month 240.6 ± 8.0-4.7 ± 7.9
Change at Month 362.1 ± 5.6-3.8 ± 7.4
Change at Month 48-1.3 ± 8.3-2.5 ± 9.0
Change at Month 60-1.0 ± 7.7-1.4 ± 11.0
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. The TEAE was an AE that began or worsened after treatment with study drug. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.

Time frame:
Baseline up to the end of Cycle 8 (cycle length = 21 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsDoxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH)Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)6263
SecondaryPercentage of Participants With Progression or Death

Progression was defined as a 25% or more increase in the size of the lesion or appearance of new lesion. If the participant did not develop an event (disease progression or death), the participant was censored at the last known tumor assessment date (or last follow-up visit without progression documented).

Time frame:
Up to 5 Years after randomization
Reported as:
Number · percentage of participants
Percentage of Participants With Progression or Death
percentage of participantsDoxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH)Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH)
Participants with progression or death11.112.7
Participants censored88.987.3
SecondaryPercentage of Participants Achieving a Pathological Complete Response (pCR) in Breast and Node

The pCR of breast and node was based upon histologic examination, as confirmed by a central panel of experts, of breast tissue resected.

Time frame:
At the end of Cycle 8 (each cycle length = 21 days)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Pathological Complete Response (pCR) in Breast and Node
percentage of participantsDoxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH)Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH)
Percentage of Participants Achieving a Pathological Complete Response (pCR) in Breast and Node38.147.6
SecondaryNumber of Participants Undergoing Breast Conservative Surgery
Time frame:
At the end of Cycle 8 (each cycle length = 21 days)
Reported as:
Count of participants · Participants
Number of Participants Undergoing Breast Conservative Surgery
ParticipantsDoxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH)Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH)
Missing data75
Had breast conservative surgery3331
Did not have breast conservative surgery2327
SecondarySeverity of Adverse Events as Characterized by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)

AEs were recorded and graded per the NCI CTCAE scale. The NCI CTCAE is a toxicity scale used to grade the severity of adverse events experienced with cancer treatment. Grade 1= Mild; Grade 2= Moderate; Grade 3= Severe; Grade 4= Life-threatening or disabling; Grade 5= Death related to AE. For summaries for the toxicity grade, participants were counted once at the greatest NCI CTCAE grade.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Severity of Adverse Events as Characterized by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
ParticipantsDoxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH)Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH)
Grade 121
Grade 2912
Grade 31918
Grade 43232
Grade 500

Adverse events

Collected over Up to 5 years after randomization. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH)0/62 (0%)18/62 (29%)62/62 (100%)
Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH)4/63 (6.3%)21/63 (33.3%)63/63 (100%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventDoxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH)Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH)
Febrile neutropeniaBlood and lymphatic system disorders9/627/63
ConstipationGastrointestinal disorders0/622/63
PyrexiaGeneral disorders1/622/63
LeukopeniaBlood and lymphatic system disorders1/620/63
CyanosisCardiac disorders1/620/63
Vertigo positionalEar and labyrinth disorders1/620/63
AstheniaGeneral disorders1/620/63
FatigueGeneral disorders1/620/63
ErysipelasInfections and infestations1/620/63
Urinary tract infectionInfections and infestations1/620/63
Most frequent other events
Showing 10 of 70
Most frequent other events
EventDoxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH)Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH)
NeutropeniaBlood and lymphatic system disorders41/6246/63
NauseaGastrointestinal disorders44/6239/63
AlopeciaSkin and subcutaneous tissue disorders37/6241/63
AstheniaGeneral disorders28/6236/63
LeukopeniaBlood and lymphatic system disorders24/6234/63
Mucosal inflammationGeneral disorders32/6225/63
DiarrhoeaGastrointestinal disorders27/6225/63
StomatitisGastrointestinal disorders21/6221/63
AnaemiaBlood and lymphatic system disorders13/6221/63
VomitingGastrointestinal disorders17/6221/63

Baseline characteristics

The set of enrolled participants included all participants who were randomized to a treatment group, regardless of whether or not a participant received any study drug.

Age, Continuous
Age, Continuous(years)Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH)Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH)Total
Mean48.8 ± 11.651.1 ± 11.349.9 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH)Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH)Total
Female6363126
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Doxorubicin (MYOCET) + Cyclophosphamide + Trastuzumab (MCH) and Docetaxel + Trastuzumab (TH)Doxorubicin (Anthracycline) + Cyclophosphamide (AC) and Docetaxel + Trastuzumab (TH)Total
White6159120
Black011
Asian101
Other134
08

Study locations

22 sites
  • Teva Investigational Site 16
    Kufstein, Austria
  • Teva Investigational Site 15
    Wien, Austria
  • Teva Investigational Site 9
    Brussels, Belgium
  • Teva Investigational Site 29
    Yvoir, Belgium
  • Teva Investigational Site 4
    Clichy Cedex, France
  • Teva Investigational Site 5
    Nancy, France
  • Teva Investigational Site 33
    Reims, France
  • Teva Investigational Site 8
    Vandoeuvre-Les-Nancy CEDEX, France
  • Teva Investigational Site 30
    Aachen, Germany
  • Teva Investigational Site 11
    Dusseldorf, Germany
  • Teva Investigational Site 25
    Dusseldorf, Germany
  • Teva Investigational Site 32
    Essen, Germany
  • Teva Investigational Site 34
    Lorrach, Germany
  • Teva Investigational Site 14
    Munchen, Germany
  • Teva Investigational Site 27
    München, Germany
  • Teva Investigational Site 20
    Napoli, Italy
  • Teva Investigational Site 23
    Roma, Italy
  • Teva Investigational Site 21
    Verona, Italy
  • Teva Investigational Site 26
    Barcelona, Spain
  • Teva Investigational Site 3
    Barcelona, Spain
  • Teva Investigational Site 1
    Lleida, Spain
  • Teva Investigational Site 2
    Zaragoza, Spain
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2008 to primary completion in Sep 2015, 83 months.

Results were first posted in Feb 2024, 8 years 5 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 83 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2008
First posted
Jul 10, 2008
StartActual
Oct 13, 2008
Primary completionActual
Sep 17, 2015
CompletionActual
Sep 17, 2015
Results first posted
Feb 23, 2024
Last update
Feb 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00712881
Lead sponsor
Cephalon, Inc.
Responsible party
Sponsor
First posted
Jul 10, 2008
Start date
Oct 13, 2008
Primary completion
Sep 17, 2015
Completion
Sep 17, 2015
Results posted
Feb 23, 2024
Last update
Feb 23, 2024

Study contacts

Teva Medical Expert
study director · Teva Branded Pharmaceutical Products R&D, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal doxorubicin

Start the discussion